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Abstract
Background & Aims—We studied the relationship between IL28B gene-related SNP
rs12979860 and early viral kinetics (day 0–28) during peginterferon and ribavirin treatment, in
173 African Americans (AA) and 188 Caucasian Americans (CA) with HCV genotype 1.
Methods—We studied the relationship between IL28B 16 gene-related SNP rs12979860 and
early viral kinetics (day 0–28) 17 during peginterferon and ribavirin treatment, in 171 African 18
Americans (AA) and 188 Caucasian Americans (CA) with HCV 19 genotype 1.
Results—Compared to non-C/C genotypes, C/C was associated with greater declines in serum
HCV RNA during phase 1 (day 0–2), phase 2 (day 7–28), and day 0–28 and higher response
(undetected HCV RNA) rates at weeks 4 and 12 in AA and CA. A static phase and increases in
HCV RNA from day 2 to 7 were more common in patients with non-C/C genotypes. C/C was also
associated with higher week 24, 48, and 72 response rates in CA (p <0.01) but not in AA. At
baseline, SNP genotype was the only independent predictor of phase 1; SNP genotype and phase 1
were independent predictors of phase 2 (p<0.001). There were no racial differences in HCV RNA
declines during phase 1, day 2–7, phase 2, and day 0–28 with the same SNP genotype. AA with C/
C and C/T genotypes had lower week 24, 48, and 72 (SVR) rates than did CA (p = 0.03). SNP C/C
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predicted higher SVR rates in AA and CA with high baseline HCV RNA (≥ 600,000 IU/ml), and
in CA with ≥ 1 log10 IU/ml decrease in HCV RNA from day 0 to 28.
Conclusions—SNP rs12979860 is strongly associated with both phase 1 and phase 2 HCV
RNA kinetics in AA and CA with HCV genotype 1.
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Introduction
A sustained virologic response (SVR) following antiviral treatment can delay liver fibrosis
progression and decrease the incidence of HCC due to chronic HCV infections [1,2].
However, less than 50% of HCV genotype 1 infected patients experience a SVR after
peginterferon plus ribavirin therapy [3,4]. SVR rates are lower in AA infected with HCV
genotype 1 compared to CA [5]. Several studies have shown a strong association between
single nucleotide polymorphisms (SNP) near the IL28B gene on chromosome 19 and SVR
following peginterferon and ribavirin treatment in patients with HCV genotype 1 [6]. The
SNP rs12979860 C/C genotype was associated with a 2–3-fold higher SVR compared to T/T
and C/T genotypes. The C-allele was much less common in AA compared to CA, and the
difference in allele frequencies was felt to explain up to 50% of the racial disparity in SVR
[6].
How genetic variation near the IL28B gene regulates treatment response to peginterferon
and ribavirin has not been completely defined. Yet, it is known that a faster decline in serum
HCV RNA during the first 28 days of therapy predicts a higher SVR [7]. Serum HCV RNA
dynamics from day 0 to 28 peginterferon, alone or combined with ribavirin show at least 2
distinct phases [8–11]. Phase 1 is characterized by a decline in serum HCV RNA from day 0
to 2, hypothesized to represent IFN effectiveness at blocking HCV production. HCV RNA
drops at a slower rate during phase 2 (day 7–28), which is thought to indicate clearance of
infected cells. The magnitude of phase 2 is a strong predictor of SVR [8,9]. In previous
studies, AA patients with HCV genotype 1 exhibited weaker phase 1 and phase 2 responses
[9,12]. Thompson et al. observed a faster decline in HCV RNA from day 0 to 14 and day 0
to 28, and higher week 4 and 12 response rates during peginterferon combination treatment
in HCV genotype 1 patients with the SNP (rs12979860) C/C compared to T/T and C/T
genotypes [13]. The relationship between IL28B SNP and phase 1 and phase 2 kinetics has
not been studied in AA and CA. However, the C/C genotype was an independent predictor
of phase 1 in European patients [14]. Based on superior efficacy to standard therapy, two
HCV NS34a protease inhibitors combined with peginterferon and ribavirin were recently
approved for treatment of HCV genotype 1 in the US [15,16]. Yet, both drugs were less
efficacious in AA compared to CA, probably related to greater resistance to peginterferon
and ribavirin in AA patients. In the present study, we defined the relationships between SNP
rs12979860 and early viral kinetics in AA and CA infected with HCV genotype 1 during
peginterferon and ribavirin treatment.
Materials and methods
Study population
The VIRAHEP-C study was described previously [5]. Briefly, 401 treatment-naïve adults
(196AA and 205 CA) with HCV genotype 1 infections received peginterferon alfa-2a 180
μg weekly and ribavirin 1000–1200 mg per day for up to 48 weeks. Adherence to
peginterferon and RBV was monitored using the electronic Medication Event Management
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System (Aardex, Zug, Switzerland). Informed consent was obtained from each patient; the
current cohort includes 361 subjects who consented to genetics studies. The study protocol
conformed to ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori
approval by the Institutional Review Board at each site.
HCV RNA kinetics day 0–28
Serum HCV RNA concentrations on day 0, 1, 2, 7, 14, and 28 were measured with the
COBAS Amplicor Hepatitis C Virus Monitor Test, 2.0™ assay (sensitivity 600 IU/ml;
Roche Molecular Diagnostics, Alameda, CA) [7]. Levels below the detection limit were
tested in duplicate with the Roche Amplicor™ assay (sensitivity >50 IU/ml). Samples
negative by Monitor Test and positive with the Amplicor assay were assigned an HCV RNA
concentration of 599 IU/ml. Phase 1 was defined as the difference in HCV RNA
concentration (log10 IU/ml) from day 0 to 1 or day 0 to 2, whichever was greater [7]. Phase
2 was defined as the best fit slope of serum HCV RNA (log10 IU/ml/wk) concentrations
from day 7 to 28.
Study endpoints
Response rates at weeks 4 (rapid virologic response or RVR), 12 (early virologic response or
EVR), 24, 48, and 72 (SVR) were defined as an undetectable serum HCV RNA (<50 IU/ml).
Viremia breakthrough was characterized by an undetectable serum HCV RNA at week 24,
but detectable at week48. Relapse was defined as an undetectable HCV RNA at week 48,
but detectable at week 72. A null response was defined as < 1 log10 IU/ml decrease in HCV
RNA from day 0 to 28.
SNP rs12979860 genotyping
Samples were genotyped for SNP rs12979860 using the allele specific discrimination kit
(ABI TaqMan) and an ABI7900HT Sequence Detection System (Applied Biosystems) as
previously described [17].
Statistical analysis
Patient demographic and clinical characteristics were compared using t-tests and Chi-square
tests. The effect of SNP genotype on virologic response was evaluated under the additive
genetic model, with the genotype variable coded as the number of C alleles (0, 1,2). Changes
in serum HCV RNA on days 1, 2, 7, 14, and 28 relative to day 0 were compared using
nonparametric tests. Phase 1 (day 0–2], phase 2 (day 7–28) and declines in serum HCV
RNA from day 2 to 7 and day 0 to 28 were compared using analysis of variance (ANOVA).
Multivariate logistic regression was used to define variables associated with SVR and early
viral kinetics phase 1 and 2. Bivariate logistic regression was used to evaluate associations
between phase 1 and phase 2 and week 4, 12, 24, 48, and 72 treatment responses. All
analyses were performed using SAS 9.2 (SAS Institute, Cary, North Carolina).
Results
Patient characteristics
Table 1 shows patient characteristics by SNP rs12979860 genotype in AA and CA. T/T and
C/T genotypes were more frequent in AA; the C/C genotype was more common in CA
(p<0.001). Baseline serum HCV RNA levels were higher in AA with C/T compared to T/T
and C/C. Baseline serum HCV RNA concentration did not vary by SNP genotype in CA.
The liver fat score was higher in CA with T/T compared to C/T and C/C. Patient age, gender
distribution, BMI, HOMA-IR score, liver fibrosis stage and adherence to peginterferon and
ribavirin did not differ by SNP genotype in either AA or CA. Compared to CA, AA were
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older, and had greater BMI (Supplementary Table 1A) and lower pretreatment serum ALT
as reported previously [5]. Also, AA patients received a lower percentage of the maximum
ribavirin dose during the first 4 and the first 24 weeks. Furthermore, AA patients had
significantly lower week 4 (RVR) (9% vs. 23%), 12 (EVR) (44% vs. 71%), 24 (52% vs.
83%), 48 (ETR) (46% vs. 79%), and 72 (SVR) (26% vs. 54%) (p <0.001) rates. Baseline
characteristics as a function of SNP rs12979860 genotype are shown in Supplementary
Table 1B. Patients with T/T and C/T had greater BMI and insulin resistance (HOMA-IR).
Patients with C/C and C/T had higher pretreatment serum HCV RNA, while those with C/C
had higher and ALT concentrations relative to non-C/C genotypes.
HCV RNA kinetics day 0–28
Compared to CA, AA patients had smaller declines in serum HCV RNA on days 1, 2, 7, 14,
and 28 (Supplementary Fig. 1), and less vigorous phase 1 (day 0–2) [0.69 + 0.63 vs. 0.98 +
0.76 log10 IU/ml; p <0.001 ANOVA], phase 2 (day 7–28) [0.38 + 0.25 vs. 0.45 + 0.28 log10
IU/ml/wk; p = 0.03], day 2–7 [0.11 + 0.5 vs. 0.1 + 0.5; p <0.001] and day 0–28 [1.5 + 1.0 vs.
2.25 + 1.23; p <0.0001] responses. A null response (<1 log10 IU/ml HCV RNA decline day
0–28) was more common in AA (37% vs. 20%; p = 0.003) and in patients with SNP non-CC
genotypes (T/T-44.2%; C/T-32.0%; C/C-9.4%; p <0.0001). Yet, AA (Fig. 1A) and CA (Fig.
1B) with the SNP C/C genotype had larger declines in serum HCV RNA on days 1, 2, 7, 14,
and 28 than those with T/T and C/T. Phase 1 (Fig. 2A), phase 2 (Fig. 2C), and day 0–28
(Fig. 2C) declines were also more robust in AA and CA with C/C relative to T/T and C/T
genotypes. Hermann et al. described a second phase starting on day 2–4 and lasting up to
day 28 in which HCV RNA was either static or increased (i.e. shoulder) followed by a third
phase of decay thought to reflect a delay in the pharmacologic activity of ribavirin [10,11].
In the present study, patients with T/T and C/T genotypes were more likely to have either a
static phase or an increase (rebound) in HCV RNA from day 2 to 7 (Fig. 1A and B). Among
patients with >1 log10 IU/ml decrease in HCV RNA from day 0 to 28, 40% of CA with CC
exhibited a static or rebound phase compared to 61% and 60% of CA with C/T and T/T (p =
0.02). The corresponding proportions in AA were 47%, 70%, and 76% (p = 0.35). However,
changes in HCV RNA from day 2 to 7 varied by SNP genotype only in the CA (Fig. 2B).
Resumption in HCV RNA decay was noted between day 7 and 28. As reported previously,
we did not observe an acceleration in HCV RNA between day 7 and 56 [7]. With one
exception, phase 1, phase 2, day 2–7, and day 0–28 declines in HCV RNA did not differ
significantly between AA and CA with the same SNP genotype. The change in HCV RNA
from day 2 to 7 was greater in CA compared to AA with C/T (p = 0.04).
Variables associated with phase 1 and phase 2 responses
In univariate analyses, CA race (p <0.0001), SNP C/C genotype (p <0.0001), Ishak liver
fibrosis score <3 (p = 0.01), greater portal tract inflammation (HAI >2; p = 0.004), and less
lobular inflammation (HAI <4; p = 0.03) at baseline were associated with a larger phase 1
decline in HCV RNA (Supplementary Table 2). CA race (p = 0.01), SNP C/C genotype (p
<0.0001) and less hepatic steatosis (p = 0.004) were associated with a faster phase 2 decline.
These 6 variables, plus body weight <75 kg (p = 0.01) and less insulin resistance (HOMA
score <2) (p = 0.03) were associated with the drop in HCV RNA from day 0 to 28
(Supplementary Table 2). SNP genotype, race and body weight were also associated with
day 2–7 change in HCV RNA. In a multivariable regression model, only SNP genotype (C/
C vs. non-C/C) was associated with phase 1 (p <0.0001). Phase 1 (stratified by <1 log10 IU/
ml vs. >1 log10 IU/ml) was added to the multivariate model for phase 2 [8,9,13]. SNP
genotype was associated with phase 2 in both groups (phase 1 <1 log10; p =0.0008; >1 log10,
p =0.011). Phase 1 (p = 0.013) predicted phase 2 only in those with <1 log10 IU/ml HCV
RNA decline in the total study sample. C/C was associated with a faster phase 2 decline rate
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in CA with either a phase 1 <1 (p = 0.003) or >1.0 (p = 0.02) log10 IU/ml, but not in AA
stratified by phase 1 (Supplementary Fig. 4).
Week 4–72 treatment responses
Compared to T/T and C/T, the SNP C/C genotype was associated with higher week 4
(RVR), 12 (EVR), 24, 48, and 72 (SVR) response rates overall (Supplementary Fig. 2).
These differences were highly significant at each time in CA (Fig. 3B), but only at weeks 4
and 12 in AA (Fig. 3A). Breakthrough rates did not vary by SNP genotype in AA patients
(Fig. 3A). In contrast, breakthrough was less frequent in CA with C/C and C/T relative to T/
T (p = 0.003) (Fig. 3B). Relapse rates did not differ by SNP genotype in either race. Similar
results were obtained when 262 patients (112 AA and 250 CA) with optimum medication
adherence (i.e. >80% of the maximum peginterferon and ribavirin doses) from day 0 to
week 24 were studied (Supplementary Fig. 3A and B). There were no racial differences in
response rates from week 4 to 72 among patients with the T/T genotype (Supplementary Fig.
5A). Among patients with C/T (Supplementary Fig. 5B) and C/C genotypes (Supplementary
Fig. 5C), CA had higher response rates at weeks 24 (p <0.01), 48 (p <0.005) and 72 (p
<0.03). Breakthrough and relapse rates did not differ between AA and CA matched for SNP
genotype. Racial differences in week 24–72 responses among patients with C/T and C/C
persisted when only patients with optimum medication adherence were analyzed.
Variables associated with SVR
Variables associated with SVR in univariate analyses in the total sample were patient race (p
<0.0001), SNP genotype (p <0.0001), baseline HCV RNA (p = 0.04), Ishak fibrosis score (p
= 0.001), and peginterferon (p = 0.005) and ribavirin adherence (p = 0.006) (Supplementary
Tables 3A–C). In a multivariable regression model for the total group, CA race, C/C
genotype (additive genetic model), and higher peginterferon and ribavirin adherence were
associated with greater odds for SVR (Table 2, model 1); higher baseline serum HCV RNA
and a higher Ishak fibrosis score were associated with a lower SVR. SNP genotype, Ishak
score, and peginterferon adherence were associated with SVR in CA; only baseline serum
HCV RNA was associated with SVR in AA (Supplementary Table 4A). SNP genotype also
predicted SVR in a recessive genetic model [OR-3.05 (1.62–5.73), p = 0.0005], but not in a
dominant model [OR-1.50 (0.74–3.03), p = 0.26] (Supplementary Tables 4B and C,
respectively).
Declines in HCV RNA during phase 1, phase 2, and both day 2–7 and day 0–28 were greater
in patients with a RVR or a SVR compared to nonresponders at weeks 4 and 72
(Supplementary Table 2). In bivariate regression analyses, RVR was more strongly
associated with phase 1 [odds ratio (OR)-4.2, 95% CI (2.4–7.3)] than with phase 2 [OR-0.1
(0.01–0.30)]. In contrast, week 24, 48, and 72 responses were more strongly associated with
phase 2 than with phase 1 [SVR: phase 1, OR-2.0 (1.4–3.1); phase 2, OR-21.8 (7.1–67.5)].
To determine the relative importance of early HCV kinetics and baseline variables to SVR,
on-treatment variables during the first 4 weeks were combined to variables in model 1
(Table 2, model 2). Baseline serum HCV RNA level (OR 0.46) and the extent of HCV RNA
decline from day 0 to 28 (OR 2.66) were strong predictors of SVR; peginterferon adherence
(OR 1.04) was weakly associated with SVR. If the day 2–7 change in serum HCV RNA was
also included in model 2, only baseline viral load was associated with SVR. Patients with a
low baseline HCV RNA (<600,000 IU/ml) had a higher SVR than those with a high baseline
RNA (>600,000 IU/ml) (AA-44% vs. 17%, p <0.001; CA-62% vs. 48%; p = 0.02) (Table 3).
SVR did not differ by SNP genotype in patients with a low baseline viral load. However, in
patients with a high baseline HCV RNA, SVR rates were 2–4 times higher in those with C/C
compared to non-C/C genotypes. In patients with C/C, SVR rates did not differ significantly
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between low and high baseline HCV RNA; in contrast, SVR rates were 2–5 times higher in
C/T and T/T patients with a low viral load.
Compared to null responders (<1 log10 IU/ml decline in HCV RNA from day 0 to 28), those
with a > 1 log10 decrease in RNA had higher SVR rates, overall and stratified by SNP
genotype (Table 3). SVR did not vary by SNP genotype in null responders. Among patients
with >1 log10 RNA decline from day 0 to 28, in contrast, CA (but not AA) with C/C had a
higher SVR than those with non-C/C genotypes. SVR increased gradually with the extent of
decline in HCV RNA from day 0 to 28 (Table 3; rows 5–7). Within each day 0–28 decline
category, however, SVR rates did not differ by SNP genotype in either AA or CA. Yet,
among patients with the same SNP genotype and either baseline viral load or day 0–28
decline category, CA tended to have higher SVR rates. In patients without an RVR, AA had
a lower SVR than CA (22% vs. 49%; p <0.001) (Supplementary Table 5). However, SVR
did not vary by SNP genotype in AA and CA with an RVR. The C/C genotype was
associated with a higher SVR in CA without an RVR (p = 0.004). SVR did not vary by SNP
genotype in patients with and without an EVR.
Discussion
SNP rs12979860 was associated with greater declines in serum HCV RNA during phase 1
(day 0–2), phase 2 (day 7–28), day 2–7, and day 0–28 and higher week 4 and 12 response
rates in both AA and CA receiving peginterferon and ribavirin therapy for HCV genotype 1.
AA had less vigorous phase 1 and 2, day 2–7, and day 0–28 declines and lower week 4 and
12 responses relative to CA that were explained largely by differences in SNP genotype
frequencies. Phase 1 and phase 2 predicted SVR, and SNP C/C (vs. non-C/C) was strongly
associated with both phases in multivariable analyses. Week 24, 48, and 72 (SVR) responses
were 2–3 times higher in CA patients with SNP C/C relative to non-C/C genotypes.
Compared to CA with C/T and C/C, week 24, 48 and 72 response rates were lower in AA,
and SVR did not vary by SNP genotype in AA.
Bochud et al. reported that SNP rs12979860 genotype is an independent predictor of the
phase 1 decline as well as higher RVR and SVR rates during peginterferon α-2a and
ribavirin therapy for HCV genotype 1 in European patients [14]. However, this SNP was not
associated with the magnitude of phase 2. Consistent with their results, SNP rs12979860
was the sole predictor of phase 1 in a multivariable regression model in the present study
[14]. In contrast to Bochud, SNP genotype and phase 1 <1 log10IU/ml were also
independently associated with phase 2. The discrepancy in results may be explained by a
difference in the definitions for phase 1- day 0–2 in present study and day 0–4 in Bochud’s
[14]. Others have reported that a phase 1 >0.5 log10IU/ml is needed for an optimum phase 2
response to peginterferon ± ribavirin [18]. The finding that phase 1 predicts phase 2 in
patients with phase <1 log10 IU/ml is in accord with this observation, and suggests there was
no phase 1 threshold for the second phase response above a 1 log10 IU/ml decrease.
However, the SNP C/C genotype predicted a faster decline in phase 2 regardless of phase 1
category, especially in CA.
In keeping with previous reports in HCV genotype 1 patients, more robust phase 1 (day 0–2)
and phase 2 (day 7–28) declines in serum HCV RNA predicted a higher SVR rate during
peginterferon and ribavirin [9]. Also, phase 2 was the better predictor of SVR than phase 1.
Furthermore, AA patients exhibited weaker phase 1, phase 2, day 2–7, and day 0–28
declines and lower response rates from week 4 to 72 (SVR) compared to CA [9,12]. The
racial disparity in early viral kinetics (day 0–28) and week 4 and 12 response rates was
strongly related to variation in SNP allele frequencies [6,13,19]. There were no racial
differences in phase 1, phase 2, and day 0–28 declines in HCV RNA and in week 4 and
Howell et al. Page 6













week 12 responses in patients grouped by SNP genotype. The lower RVR in AA with the C/
T genotype was an exception that might be explained by the small number of AA with a
RVR. We also observed an association between SNP rs12979860 genotype and the extent of
HCV RNA decay from day 2 to 7, the transition between phase 1 and phase 2. Compared to
C/C, patient with non-C/C genotypes were more likely to have either a static phase or
rebound in HCV RNA. This variability is likely related to differences in IFN effectiveness
(i.e. phase 1). Indeed, the change in HCV RNA from day 2 to 7 was also more strongly
correlated with the extent of phase 1 than the phase 2 slope (data not shown). Furthermore,
the rebound in HCV RNA from day 2 to 7 was related to a decline in serum peginterferon
levels between the first 2 peginterferon injections and was inversely proportional to the
ribavirin plasma concentration in previous studies [18,20]. The importance of ribavirin to
the phase 2 decline rate in HCV genotype 1 patients is known to vary inversely with IFN
effectiveness (i.e. phase 1) [21]. Ribavirin adherence did not differ by SNP genotype in
either race. Assuming similar ribavirin exposure, lower IFN effectiveness could explain why
a flat or rebound phase from day 2 to 7 and a weaker phase 2 responses were more prevalent
in patients with T/T and C/T genotypes [21].
Thompson et al. previously studied the relationship between SNP rs12979860 and treatment
response to initial peginterferon and ribavirin therapy for HCV genotype 1 in US patients
[13]. In keeping with their results, we observed higher week 4 (RVR), 12, 24, 48, and 72
(SVR) response rates in CA patients with C/C compared to non-C/C genotypes [13].
Likewise, the C/C genotype predicted a higher SVR in CA without a RVR. Furthermore,
SNP genotype did not influence the SVR rate in either race based on week 12 (EVR). In
contrast, the C/C genotype was only associated with higher week 4 (RVR) and 12 (EVR)
responses in AA in the current study. Week 24–72 response rates did not vary by SNP
genotype in AA. McCarthy also found no association between this SNP and SVR in 58 AA
patients infected with HCV genotype 1 [19]. These inconsistencies may be related to the
smaller sample size and a lower percentage of AA with C/C in the present study.
Nevertheless, SVR was lower in AA compared to CA with C/C and race, C/C genotype,
serum HCV RNA, and Ishak fibrosis score were independently associated with SVR in this
and other studies in American patients [6,13,19]. Higher peginterferon adherence was also
weakly associated with SVR, but this did not account for differences in treatment response
based on race and SNP genetics [5,7].
A multivariable model was used to explore the link between baseline, drug adherence, and
early viral kinetics variables associated with SVR (Table 2, model 2 compared to model 1).
Only baseline serum HCV RNA, day 0–28 HCV RNA decline, and peginterferon adherence
were associated with SVR in this model. Other baseline variables (SNP genotype, race, and
Ishak’s fibrosis score) were no longer significant. The day 0–28 decrease in HCV RNA
overall was a better predictor of SVR than phase 1 and 2 and the week 4 response (i.e.
RVR). The C/C genotype was associated with a higher SVR in AA and CA with a high
baseline serum HCV RNA (>600,000 IU/ml) and in CA with >1 log10IU/ml fall in HCV
RNA from day 0 to 28. SNP genotype did not influence SVR in patients with a baseline
HCV RNA <600,000 IU/ml or a null response. Thus, the greatest clinical utility of SNP
genotype for predicting SVR to initial peginterferon and ribavirin for HCV genotype 1
might be in patients with high baseline viral loads. Yet, grouped by SNP genotype and either
baseline HCV RNA or day 0–28 decline in RNA, AA had lower SVR rates than CA.
Presumably these racial differences reflect biological processes that are not linked to SNP
rs12979860.
In conclusion, SNP 12979860 is strongly associated with the strength of phase 1 (day 0–2),
phase 2 (day 7–28), and the day 2–7 response during early HCV RNA kinetics and week 4
and 12 response rates during peginterferon and ribavirin treatment in both AA and CA
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patients infected with HCV genotype 1. In pharmacodynamic terms, these findings suggest
that this SNP predicts IFN effectiveness at blocking HCV production and clearance of
infected hepatocytes, respectively. SNP 12979860 explained more than 50% of the disparity
in early viral kinetics and viral clearance during the first 12 weeks between AA and CA.
This SNP was strongly associated with week 24, 48, and 72 (SVR) responses in CA patients,
but did not predict treatment responses beyond week 12 in AA patients. A better
understanding of the biological basis for the effect of IL28B gene-related SNPs on treatment
response and of racial disparities in week 24–72 response to peginterferon and ribavirin
treatment might identify novel therapeutic targets for HCV genotype 1.
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EVR early virologic response
CI confidence interval
D28 day 28
HCV hepatitis C virus
IFN interferon
BMI body mass index




R response or responder[s]
RVR rapid virologic response
SNP single nucleotide polymorphism
SVR sustained virologic response
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Fig. 1. Serum HCV RNA day 0–28 AA (A) and CA (B)
Serum HCV RNA concentrations were measured as per Materials and methods. Results
compared using Kruskal-Wallis tests.
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Fig. 2. Early HCV RNA kinetics phases (day 0–28)
Changes in serum HCV RNA concentrations, (A) phase 1 (day 0–2), (B) day 2–7; (C) phase
2 (day 7–28); (D) day 0–28. Results compared by ANOVA.
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Fig. 3. SVR by SNP rs12979860 genotype in AA (A) and CA (B)
Results compared by regression analysis and additive genetic model.
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Table 2
Variables associated with SVR in multivariable regression model.a
Model 1 Model 2


































Phase 1 - 0.69 (0.31–1.52)
p = 0.36






RVR - 1.8 (0.46–6.98)
p = 0.4
a
Results show odds ratio and 95% confidence intervals (CI); n = 361.
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